Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

rEV-131 studied in new trial for inflammation following cataract surgery

June 23, 2006

ISTA licenses new investigational glaucoma products from Senju

June 22, 2006

Series A financing to fund development of Danube's oral glaucoma therapy

June 19, 2006

MabThera recommended for European approval for rheumatoid arthritis

June 7, 2006

Initial increase in vision from baseline with monthly dosing of Lucentis

June 7, 2006

New therapeutic agents for ocular disorders disclosed

June 6, 2006

Macugen, new wet AMD treatment in U.K.

June 1, 2006

ISTA begins pivotal studies for once-daily Xibrom

May 31, 2006

Orally available calpain inhibitor provides in vivo neuroprotection against retinal ischemia

May 31, 2006

Isotechnika licenses ISA-247 to Lux for ophthalmic indications

May 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...